<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25730">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771795</url>
  </required_header>
  <id_info>
    <org_study_id>SB3-G31-BC-E</org_study_id>
    <nct_id>NCT02771795</nct_id>
  </id_info>
  <brief_title>A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC</brief_title>
  <official_title>A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or
      Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of congestive heart failure and LVEF decrease</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of symptomatic congestive heart failure (CHF) NYHA class II, III, and IV and asymptomatic significant LVEF decrease</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB3 (proposed trastuzumab biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin (trastuzumab)</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB3 (proposed trastuzumab biosimilar)</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>SB3 (proposed trastuzumab biosimilar)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have completed the study treatment of SB3-G31-BC.

          -  Subjects must provide informed consent.

        Exclusion Criteria:

          -  Subjects unwilling to follow the study requirements are not eligible for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 13, 2016</lastchanged_date>
  <firstreceived_date>May 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Cancer</keyword>
  <keyword>Breast</keyword>
  <keyword>Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
